GLOBAL LIQUID BIOPSY MARKET FORECAST 2018-2026

  • You are here:
  • Home
  • Reports
  • GLOBAL LIQUID BIOPSY MARKET FORECAST 2018-2026

GLOBAL LIQUID BIOPSY MARKET FORECAST 2018-2026

The global liquid biopsy market was valued at $740.6 million in 2017 & is estimated to generate net revenue of approximately $4736.8 million by 2026, growing at a CAGR of 22.97%. A liquid biopsy is rapidly gaining traction as a supplement or alternative to doing a tissue biopsy for applications in reproductive health, cancer and transplant medicine. The Liquid Biopsy market is primarily driven by the following factors:

GLOBAL LIQUID BIOPSY MARKET FORECAST 2018-2026

Global Liquid Biopsy Market by Products (Ctcs and Ctdna, Exosome) by Analysis Purpose (Early Detection/screening, Therapy Guidance, Monitoring, Diagnosis) by End User (Physicians ‘office Laboratories, Hospitals, Clinical Diagnostic Laboratories) by Analysis Platform (Ngs, Microarray, Pcr, Proteomics, Other Analysis Platform) by Biomaker Types (Nucleic Acids, Proteins, Extracellular Vesicles, Cells) by Indication (Nipt, Cancer, Transplant) & by Geography

Request free sample

The global liquid biopsy market was valued at $740.6 million in 2017 & is estimated to generate net revenue of approximately $4736.8 million by 2026, growing at a CAGR of 22.97%. A liquid biopsy is rapidly gaining traction as a supplement or alternative to doing a tissue biopsy for applications in reproductive health, cancer and transplant medicine. The Liquid Biopsy market is primarily driven by the following factors:

  • Rising government initiatives
  • Growing pervasiveness of cancer cases in the older populace
  • Growing number of diagnostic centres
  • The growth of precision medicine
  • The emergence of tissue/ tumour-agnostic drugs

Global Liquid Biopsy Market

To learn more about this report, request a free sample copy

The important factors increasing growth in the Global Liquid Biopsy Market include the rising government initiatives and the growing pervasiveness of cancer cases in the older populace. Countries such as Australia, the UK, and the US are among the few developed countries that have mandated cancer check-ups in medical facilities. The increasing older populace is one of the chief factors for increased adoption of liquid biopsy tests. Ageing leads to a decreased immune capacity of the body.

The Indication, Biomarker types and Analysis Platform of Liquid Biopsy market are critical segments of the liquid biopsy market. NIPT assays capture and analyze circulating cell-free DNA (cfDNA) in the mother’s blood to assess the genetic status of the embryo. A liquid biopsy is well suited for the cancer market, as it fits into the paradigm shift currently underway for cancer care. The transplant market represents an attractive opportunity for liquid biopsy companies. The main biomarker types used in liquid biopsy include circulating cell-free nucleic acids (cfDNA). The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future. EVs are promising biomarkers for a liquid biopsy because they contain a diverse collection of biomolecules, including DNA, RNA, and proteins. The NGS industry is very concentrated, with Illumina being the market leader, followed by Thermo Fisher Scientific. Microarray technology has been widely used in cancer research for more than a decade. Proteomics platforms include mass spectrometry (MS) and biochips (lab-on-a-chip, planar arrays, and bead-based arrays).

Lacks of consensus on standard operating procedures (Sops) and poor compensation structures are the major factors hindering the Liquid Biopsy market. The reimbursement and treatment monitoring for liquid biopsy is limited, and it is performed in few laboratories. The poor reimbursement system is a major restraint which restricts the individuals to go for cancer detection tests and affects cancer biomarkers market in a negative way.

The Global Liquid Biopsy market segments include Indication, Biomarker types, Analysis Platform, Analysis purpose, Products and End users.

Indications are segmented into:

  • NIPT
  • Cancer
    • Cancer types
      • Pan-cancer
      • Lung
      • Gynecologic
      • Bladder
      • Prostate
      • Breast
      • Haematological
      • Colorectal
      • Brain
      • Gist (gastrointestinal stromal tumours)
      • Kidney
      • Melanoma
      • Pancreatic
      • Thyroid
    • Cancer analysis purpose
      • Therapy guidance
      • Monitoring
      • Diagnosis
      • Early detection/screening
    • Cancer analysis method
      • NGS
      • PCR
      • Proteomics
      • Microarray
  • Transplant

Biomarker types are segmented into:

  • Nucleic acids
  • Proteins
  • Extracellular Vesicles
  • Cells

Analysis Platforms are segmented into:

  • NGS
  • Microarray
  • PCR
  • Proteomics
  • Other analysis platform

Analysis purposes are segmented into:

  • Early detection/screening
  • Therapy guidance
  • Monitoring
  • Diagnosis

Products are segmented into:

  • CTCS AND CTDNA
  • Exosome

End users are segmented into:

  • Physicians ‘office laboratories
  • Hospitals
  • Clinical diagnostic laboratories

This report covers the present market conditions and the growth prospects of the Global Liquid Biopsy Market for 2018-2026 and considered the revenue generated through the sales of Liquid Biopsy for Indication, Biomarker types, Analysis Platform, Analysis purpose, Products and End users to calculate the market size by considering 2017 as the base year.

Geographically, the Global Liquid Biopsy Market has been segmented on the basis of four major regions, which include:

  • North America: The United States & Canada
  • Asia-Pacific: Japan, China, India, Japan & Rest of APAC
  • Europe: The United Kingdom, France, Germany, Italy, Spain, Russia & Rest of Europe
  • Rest of World: Latin America & Middle East and North Africa

The Liquid Biopsy market in North America is expected to hold the largest share by 2026 owing to the increasing number of cancer cases, which are increasing the liquid biopsy demand. The US and Canada have superior biopsy technologies specializing in the detection of diseases at early stages. This can significantly reduce the mortality rates of these countries. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the Liquid Biopsy market. The liquid biopsy market in APAC is witnessing the fastest growth. There is a possibility of major vendors in the market shifting their manufacturing, sales, and distribution facilities to APAC to leverage on the attractive proposition of lower cost of land and material, easy availability of labour, and access to a large patient market.

The Liquid Biopsy Market is segmented on the basis of Analysis purpose which is sub-divided into early detection/screening, Therapy guidance, Monitoring & Diagnosis. The  Products segment is sub-divided into CTCs and ctDNA while the End-user segment is sub-divided into Physicians’ office laboratories, Hospitals & Clinical diagnostic laboratories. The number of patient visits to physicians’ office laboratories is increasing. Large multispecialty hospitals and hospital groups that work under government sponsorship or through private entities are the key end-users, who influence the market growth. The global early detection/screening market is estimated to grow at a CAGR of xx % during the forecast period. Monitoring diagnostics are used to assess cancer’s aggressiveness or recurrence. Companies are focusing on developing high-end systems that can detect the CTCs and ctDNA in the blood through molecular characterization

The major market players in the Global Liquid Biopsy Market are:

  • AGILENT TECHNOLOGIES, INC.
  • AD-TECH MEDICAL INSTRUMENT CORP
  • BOSTON SCIENTIFIC CORPORATION
  • CINTEC MEDICAL LTD
  • FISCHER MEDICAL TECHNOLOGIES LLC

Company Profiles covers analysis of important players.

Agilent Technologies, Inc. is a USA based company having headquarters in Santa Clara, California. The company was established in 1999. The company offers services, software, reagents, instruments, and consumables to applied chemical, life sciences and diagnostics markets. Fischer Medical Technologies LLC (Fischer Medical) is a medical device manufacturing company that designs and sells medical systems for the healthcare sectors. The company provides products for use in breast imaging, breast biopsy, and electrophysiology stimulation.

Key Findings of the Global Liquid Biopsy market:

  • Cell-free DNA (cfDNA) and circulating tumour DNA (ctDNA) are key biomarkers for liquid biopsy tests
  • NIPT indication holds the largest market share
  • PCR is the faster-growing analysis platform
  • Early detection/screening analysis constitutes a bigger market
  • North America holds the largest market share in the global biopsy market
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • CELL-FREE DNA (CFDNA) AND CIRCULATING TUMOR DNA (CTDNA) ARE KEY BIOMARKERS FOR LIQUID BIOPSY TESTS
      • NIPT INDICATION HOLDS THE LARGEST MARKET SHARE
      • PCR ISTHE FASTER GROWING ANALYSIS PLATFORM
      • EARLY DETECTION/SCREENING ANALYSIS CONSTITUTES THE BIGGER MARKET
      • NORTH AMERICA HOLDS THE LARGEST MARKET SHARE IN THE GLOBAL BIOPSY MARKET
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • RISING GOVERNMENT INITIATIVES
      • GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
      • GROWING NUMBER OF DIAGNOSTIC CENTERS
      • GROWTH OF PRECISION MEDICINE
      • EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
    • MARKET RESTRAINTS
      • LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
      • POOR COMPENSATION STRUCTURES
    • MARKET OPPORTUNITIES
      • TECHNOLOGICAL ADVANCEMENT
      • GROWING NUMBER OF CANCER PATIENTS
    • MARKET CHALLENGES
      • LACK OF REIMBURSEMENT
      • LACK OF SKILLED PROFESSIONALS
  1. MARKET SEGMENTATIONS
    • MARKET BY PRODUCTS 2018-2026
      • CTCS AND CTDNA
      • EXOSOME
    • MARKET BY ANALYSIS PURPOSE 2018-2026
      • EARLY DETECTION/SCREENING
      • THERAPY GUIDANCE
      • MONITORING
      • DIAGNOSIS
    • MARKET BY END USER 2018-2026
      • PHYSICIAN’S ‘OFFICE LABORATORIES’
      • HOSPITALS
      • CLINICAL DIAGNOSTIC LABORATORIES
    • MARKET BY ANALYSIS PLATFORM 2018-2026
      • NGS
      • MICROARRAY
      • PCR
      • PROTEOMICS
      • OTHER ANALYSIS PLATFORM
    • MARKET BY BIOMARKER TYPES 2018-2026
      • NUCLEIC ACIDS
      • PROTEINS
      • EXTRACELLULAR VESICLES
      • CELLS
    • MARKET BY INDICATION 2018-2026
      • NIPT
      • CANCER
        • CANCER TYPES
          • PAN-CANCER
          • LUNG
          • GYNECOLOGIC
          • BLADDER
          • PROSTATE
          • BREAST
          • HEMATOLOGICAL
          • COLORECTAL
          • BRAIN
          • GIST (GASTROINTESTINAL STROMAL TUMORS)
          • KIDNEY
          • MELANOMA
          • PANCREATIC
          • THYROID
        • CANCER ANALYSIS PURPOSE
          • THERAPY GUIDANCE
          • MONITORING
          • DIAGNOSIS
          • EARLY DETECTION/SCREENING
        • CANCER ANALYSIS METHOD
          • NGS
          • PCR
          • PROTEOMICS
          • MICROARRAY
      • TRANSPLANT
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTES
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF RIVALRY
    • LIQUID BIOPSY PIPELINE
    • PATENT ANALYSIS
    • MARKET TRENDS
      • NEW PLAYERS APPROACH VENTURE CAPITALISTS TO ENTER INTO NICHE MARKETS
      • DIRECT-TO-CONSUMER TESTING
    • KEY LIQUID BIOPSY INITIATIVES
  2. GEOGRAPHY ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • RUSSIA
      • REST OF EUROPE
    • ASIA-PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • SOUTH KOREA
      • REST OF APAC
    • REST OF WORLD
      • MIDDLE EAST AND NORTH AFRICA (MENA)
      • LATIN AMERICA
  1. COMPANY PROFILES
    • COMPETITIVE LANDSCAPE
      • LIST OF ACQUISITIONS
      • STRATEGIC ALLIANCES
    • AD-TECH MEDICAL INSTRUMENT CORP
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • AGILENT TECHNOLOGIES, INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ARGON MEDICAL DEVICES INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BRAUN MELSUNGEN AG
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BECTON, DICKINSON
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BOSTON SCIENTIFIC CORPORATION
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BIO-RAD LABORATORIES, INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • R. BARD, INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • CINTEC MEDICAL LTD
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • COOK GROUP INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • FISCHER MEDICAL TECHNOLOGIES LLC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • PLANMECA OY
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • ROCHE DIAGNOSTICS LTD
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • QIAGEN N.V.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES

TABLE LIST

TABLE  1      GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  2      LIQUID BIOPSY BIOMARKER CLASSES

TABLE  3      GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES

TABLE  4      GLOBAL LIQUID BIOPSY MARKET BY PRODUCTS 2018-2026 ($ MILLION)

TABLE  5      GLOBAL LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2018-2026 ($ MILLION)

TABLE  6      GLOBAL LIQUID BIOPSY MARKET BY END USER  2018-2026 ($ MILLION)

TABLE  7      GLOBAL LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2018-2026 ($ MILLION)

TABLE  8      NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES

TABLE  9      ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS

TABLE  10    DROPLET DIGITAL PCR INDUSTRY

TABLE  11    GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPES  2018-2026 ($ MILLION)

TABLE  12    CELL DIFFERENTIATORS

TABLE  13    GLOBAL LIQUID BIOPSY MARKET BY INDICATION 2018-2026 ($ MILLION)

TABLE  14    GLOBAL LIQUID BIOPSY MARKET IN NIPT BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  15    ETHICAL ISSUES ASSOCIATED WITH NIPT

TABLE  16    CELL DIFFERENTIATORS

TABLE  17    LIMITATIONS OF SOLID BIOPSY IN CANCER APPLICATIONS

TABLE  18    GLOBAL LIQUID BIOPSY MARKET IN CANCER BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  19    GLOBAL CANCER  MARKET BY CANCER TYPES 2018-2026 ($ MILLION)

TABLE  20    PROSTATE CANCER TESTING INDUSTRY

TABLE  21    MOLECULAR THYROID NODULE CLASSIFIER TEST COMPANY POSITIONING

TABLE  22    GLOBAL CANCER  MARKET BY CANCER ANALYSIS PURPOSE  2018-2026 ($ MILLION)

TABLE  23    EARLY DETECTION TISSUE OF ORIGIN APPROACHES

TABLE  24    GLOBAL CANCER  MARKET IN CANCER ANALYSIS METHOD 2018-2026 ($ MILLION)

TABLE  25    PIPELINE OF LIQUID BIOPSY IN NORTH AMERICA

TABLE  26    PIPELINE OF LIQUID BIOPSY IN EUROPE

TABLE  27    PIPELINE OF LIQUID BIOPSY IN APAC

TABLE  28    CTC-RELATED PATENTS

TABLE  29    CELL-FREE DNA-RELATED PATENTS RELATED PATENTS

TABLE  30    GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  31    NORTH AMERICA LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

TABLE  32    EUROPE LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

TABLE  33    ASIA PACIFIC LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

TABLE  34    REST OF WORLD LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE LIST

FIGURE  1    GLOBAL LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  2    RURAL POPULATIONS IN DEVELOPING COUNTRIES 2017 (%)

FIGURE  3    GLOBAL LIQUID BIOPSY MARKET IN CTCS AND CTDNA 2018-2026 ($ MILLION)

FIGURE  4    GLOBAL LIQUID BIOPSY MARKET IN EXOSOME 2018-2026 ($ MILLION)

FIGURE  5    GLOBAL LIQUID BIOPSY MARKET IN EARLY DETECTION/SCREENING 2018-2026 ($ MILLION)

FIGURE  6    GLOBAL LIQUID BIOPSY MARKET IN THERAPY GUIDANCE 2018-2026 ($ MILLION)

FIGURE  7    GLOBAL LIQUID BIOPSY MARKET IN MONITORING 2018-2026 ($ MILLION)

FIGURE  8    GLOBAL LIQUID BIOPSY MARKET IN DIAGNOSIS 2018-2026 ($ MILLION)

FIGURE  9    GLOBAL LIQUID BIOPSY MARKET IN PHYSICIANS OFFICE LABORATORIES  2018-2026 ($ MILLION)

FIGURE  10  GLOBAL LIQUID BIOPSY MARKET IN  HOSPITALS 2018-2026 ($ MILLION)

FIGURE  11  GLOBAL LIQUID BIOPSY MARKET IN CLINICAL DIAGNOSTIC LABORATORIES  2018-2026 ($ MILLION)

FIGURE  12  GLOBAL LIQUID BIOPSY MARKET IN NGS 2018-2026 ($ MILLION)

FIGURE  13  GLOBAL LIQUID BIOPSY MARKET IN MICROARRAY 2018-2026 ($ MILLION)

FIGURE  14  GLOBAL LIQUID BIOPSY MARKET IN PCR 2018-2026 ($ MILLION)

FIGURE  15  GLOBAL LIQUID BIOPSY MARKET IN PROTEOMICS 2018-2026 ($ MILLION)

FIGURE  16  GLOBAL LIQUID BIOPSY MARKET IN OTHER ANALYSIS PLATFORM 2018-2026 ($ MILLION)

FIGURE  17  GLOBAL LIQUID BIOPSY MARKET IN NUCLEIC ACIDS 2018-2026 ($ MILLION)

FIGURE  18  GLOBAL LIQUID BIOPSY MARKET IN PROTEINS 2018-2026 ($ MILLION)

FIGURE  19  GLOBAL LIQUID BIOPSY MARKET IN EXTRACELLULAR VESICLES 2018-2026 ($ MILLION)

FIGURE  20  GLOBAL LIQUID BIOPSY MARKET IN CELLS 2018-2026 ($ MILLION)

FIGURE  21  GLOBAL LIQUID BIOPSY MARKET IN NIPT 2018-2026 ($ MILLION)

FIGURE  22  GLOBAL LIQUID BIOPSY MARKET IN CANCER 2018-2026 ($ MILLION)

FIGURE  23  GLOBAL CANCER  MARKET IN PAN-CANCER 2018-2026 ($ MILLION)

FIGURE  24  GLOBAL CANCER  MARKET IN LUNG 2018-2026 ($ MILLION)

FIGURE  25  GLOBAL CANCER  MARKET IN GYNECOLOGIC 2018-2026 ($ MILLION)

FIGURE  26  GLOBAL CANCER  MARKET IN BLADDER 2018-2026 ($ MILLION)

FIGURE  27  GLOBAL CANCER  MARKET IN PROSTATE 2018-2026 ($ MILLION)

FIGURE  28  GLOBAL CANCER  MARKET IN BREAST 2018-2026 ($ MILLION)

FIGURE  29  GLOBAL CANCER  MARKET IN HEMATOLOGICAL 2018-2026 ($ MILLION)

FIGURE  30  GLOBAL CANCER  MARKET IN COLORECTAL 2018-2026 ($ MILLION)

FIGURE  31  GLOBAL CANCER  MARKET IN BRAIN 2018-2026 ($ MILLION)

FIGURE  32  GLOBAL CANCER  MARKET IN GIST (GASTROINTESTINAL STROMAL TUMORS) 2018-2026 ($ MILLION)

FIGURE  33  GLOBAL CANCER  MARKET IN KIDNEY 2018-2026 ($ MILLION)

FIGURE  34  GLOBAL CANCER  MARKET IN MELANOMA 2018-2026 ($ MILLION)

FIGURE  35  GLOBAL CANCER  MARKET IN PANCREATIC 2018-2026 ($ MILLION)

FIGURE  36  GLOBAL CANCER  MARKET IN THYROID 2018-2026 ($ MILLION)

FIGURE  37  GLOBAL CANCER  MARKET IN THERAPY GUIDANCE  2018-2026 ($ MILLION)

FIGURE  38  GLOBAL CANCER  MARKET IN MONITORING 2018-2026 ($ MILLION)

FIGURE  39  GLOBAL CANCER  MARKET IN DIAGNOSIS  2018-2026 ($ MILLION)

FIGURE  40  GLOBAL CANCER  MARKET IN EARLY DETECTION/SCREENING 2018-2026 ($ MILLION)

FIGURE  41  GLOBAL CANCER  MARKET IN NGS 2018-2026 ($ MILLION)

FIGURE  42  GLOBAL CANCER  MARKET IN PCR 2018-2026 ($ MILLION)

FIGURE  43  GLOBAL CANCER  MARKET IN PROTEOMICS 2018-2026 ($ MILLION)

FIGURE  44  GLOBAL CANCER  MARKET IN MICROARRAY 2018-2026 ($ MILLION)

FIGURE  45  GLOBAL LIQUID BIOPSY MARKET IN TRANSPLANT 2018-2026 ($ MILLION)

FIGURE  46  NORTH AMERICA LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  47  THE UNITED STATES BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  48  NEW CANCER CASES AND CANCER DEATHS IN THE US 2016-2020 (PER 100,000 POPULATION)

FIGURE  49  CANADA LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  50  EUROPE  LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  51  THE UNITED KINGDOM  LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  52  FRANCE  LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  53  GERMANY  LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  54  ITALY  LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  55  SPAIN LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  56  RUSSIA  LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  57  REST OF EUROPE LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  58  ASIA PACIFIC  LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  59  JAPAN LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  60  CHINA LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  61  INDIA LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  62  SOUTH KOREA LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  63  REST OF APAC LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  64  REST OF WORLD LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  65  MIDDLE EAST AND NORTH AFRICA LIQUID BIOPSY MARKET 2018-2026 ($ MILLION)

FIGURE  66  LATIN AMERICA BIOPSY MARKET 2018-2026 ($ MILLION)

  1. MARKET SEGMENTATIONS
    • MARKET BY PRODUCTS 2018-2026
      • CTCS AND CTDNA
      • EXOSOME
    • MARKET BY ANALYSIS PURPOSE 2018-2026
      • EARLY DETECTION/SCREENING
      • THERAPY GUIDANCE
      • MONITORING
      • DIAGNOSIS
    • MARKET BY END USER 2018-2026
      • PHYSICIANS ‘OFFICE LABORATORIES
      • HOSPITALS
      • CLINICAL DIAGNOSTIC LABORATORIES
    • MARKET BY ANALYSIS PLATFORM 2018-2026
      • NGS
      • MICROARRAY
      • PCR
      • PROTEOMICS
      • OTHER ANALYSIS PLATFORM
    • MARKET BY BIOMARKER TYPES 2018-2026
      • NUCLEIC ACIDS
      • PROTEINS
      • EXTRACELLULAR VESICLES
      • CELLS
    • MARKET BY INDICATION 2018-2026
      • NIPT
      • CANCER
        • CANCER TYPES
          • PAN-CANCER
          • LUNG
          • GYNECOLOGIC
          • BLADDER
          • PROSTATE
          • BREAST
          • HEMATOLOGICAL
          • COLORECTAL
          • BRAIN
          • GIST (GASTROINTESTINAL STROMAL TUMORS)
          • KIDNEY
          • MELANOMA
          • PANCREATIC
          • THYROID
        • CANCER ANALYSIS PURPOSE
          • THERAPY GUIDANCE
          • MONITORING
          • DIAGNOSIS
          • EARLY DETECTION/SCREENING
        • CANCER ANALYSIS METHOD
          • NGS
          • PCR
          • PROTEOMICS
          • MICROARRAY
      • TRANSPLANT
  1. GEOGRAPHY ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • ITALY
      • SPAIN
      • RUSSIA
      • REST OF EUROPE
    • ASIA-PACIFIC
      • JAPAN
      • CHINA
      • INDIA
      • SOUTH KOREA
      • REST OF APAC
    • REST OF WORLD
      • MIDDLE EAST AND NORTH AFRICA (MENA)
      • LATIN AMERICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now